Drug intelligence / Profile preview

Lindafer

Development stage: Unknown
Lead developer: Spey Medical
Modality: Small Molecules
Administration: Oral

Overview

Lindafer is an oral antianemic multivitamin and mineral supplement developed by SPEY. It is formulated as a capsule containing ferrous bisglycinate (a highly bioavailable, gentle chelated form of iron), folic acid (pteroylmonoglutamic acid), vitamin C (L-ascorbic acid), vitamin B6 (pyridoxine hydrochloride), and vitamin B12 (cyanocobalamin). The product is designed to support the increased demand for iron and folic acid, particularly in pregnant and breastfeeding women, physically active individuals, blood donors, and vegetarians. It helps prevent and treat iron deficiency and anemia by promoting normal hematopoiesis and red blood cell formation.

Brand names: LindaferLindafer Plus
Other names: ferrous bisglycinate + folic acid + ascorbic acid + pyridoxine + cyanocobalaminiron bisglycinate + folic acid + vitamin C + vitamin B6 + vitamin B12

Beyond the preview

Go deeper on Lindafer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lindafer.